Transforming Ordinary Cells with Advanced Technology
CiRC converts one cell type to another using a proprietary cocktail of small molecules and growth factors.
Our allogeneic, off-the-shelf therapies are developed using readily sourced, cGMP-grade cell lines without the use of stem cells, enabling significant competitive and manufacturing advantages.
Transforming Ordinary Cells with Advanced Technology
CiRC converts one cell type to another using a proprietary cocktail of small molecules and growth factors. CiRC’s investigational technology can be used to directly reprogram cells within the body (in-situ) or as a cell replacement therapy.
Transforming Ordinary Cells with Advanced Technology
CiRC converts one cell type to another using a proprietary cocktail of small molecules and growth factors. CiRC’s investigational technology can be used to directly reprogram cells within the body (in-situ) or as a cell replacement therapy.
Cell Replacement Therapy
Cell replacement therapy converts fibroblasts from a master cell bank into photoreceptor or dopaminergic neuron-like cells. The chemically driven method consistently produces a uniform cell group with little or no purification needed. It’s a highly efficient, low-waste process that avoids the complexities of other cell therapies.
Cell Replacement Therapy
Cell replacement therapy converts fibroblasts from a master cell bank into photoreceptor or dopaminergic neuron-like cells. The chemically driven method consistently produces a uniform cell group with little or no purification needed. It’s a highly efficient, low-waste process that avoids the complexities of other cell therapies.
Cell Replacement Therapy
Cell replacement therapy converts fibroblasts from a master cell bank into photoreceptor or dopaminergic neuron-like cells. The chemically driven method consistently produces a uniform cell group with little or no purification needed. It’s a highly efficient, low-waste process that avoids the complexities of other cell therapies.
Pipeline
1. Orphan Drug Designation
2. Investigational New Drug
3. Retinal Pigment Epithelium
Pipeline
Pipeline
1. Orphan Drug Designation
2. Investigational New Drug
3. Retinal Pigment Epithelium
